Current Report Filing (8-k)
August 15 2017 - 9:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
August
15, 2017 (August 14, 2017)
HEMISPHERX
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-27072
|
|
52-0845822
|
(state
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
(Identification
No.)
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA
|
|
19103
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(215) 988-0080
1617
JFK Boulevard, Suite 500, Philadelphia, PA 19103
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
2.02 Results of Operations and Financial Condition
On
August 14, 2017, Hemispherx Biopharma, Inc. (the “Company”) filed its quarterly report on Form 10-Q for the quarter
ended June 30, 2017 and, thereafter, issued a press release announcing its financial results for that quarter. A copy of the press
release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As
noted in the press release, the Company will host a conference call at 1:00 PM Eastern Daylight Time (EDT) on Tuesday, August
15, 2017 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the
call.
Conference Call Information
Date:
|
Tuesday,
August 15, 2017
|
Time:
|
1:00
PM EDT
|
Dial-in
numbers:
|
800-346-7359
(domestic)
|
|
973-528-0008
(international)
|
Conference
number:
|
27781
|
Questions:
|
ir@hemispherx.net
by 5:00 p.m. EDT on Monday, August 14, 2017
|
|
http://ir.hemispherx.net/Events_Presentations
|
Item
7.01 Regulation FD Disclosure.
The
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,”
Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As
such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the
Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific
reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality
of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No. Description
99.1
|
Press
Release dated August 15, 2017
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
August 15, 2017
|
HEMISPHERX BIOPHARMA, INC.
|
|
|
|
|
By:
|
/s/
Thomas K. Equels
|
|
|
Thomas
K. Equels, President & CEO
|
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2023 to Apr 2024